Phase VC

phasecapital.co

VCMatch tracks Phase VC as an investor focused on Biotech, Medtech, and Digital Health companies, Pre-Seed and Seed rounds, and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Medtech, Digital Health

Geography

United States

Investment Thesis

Phase Capital targets early-stage, tech-enabled life sciences companies — specifically investing in “pre-seed to Series A companies at the convergence of technology, biology, and data science.” The firm focuses on platform and tool builders that “convert biological complexity into technological opportunity,” partnering with technical founders who treat “biology as technology’s next frontier,” and leverages an advisor network and ecosystem events to create curated, interdisciplinary deal flow and founder support.

Is Phase VC right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Phase VC is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, Digital Health, and Healthtech, especially across United States.

Focus statement

Phase Capital "invests in pre-seed to Series A companies at the convergence of technology, biology, and data science," backing "next-generation tools that convert biological complexity into technological opportunity — from life-changing therapeutics to scalable, sustainable solutions across industry and society."

Value Add

Explicit thesis at the intersection of technology + biology + data science (stated repeatedly on the site).
Stage-focused on pre-seed through Series A, targeting early company formation and scaling.
Preference for platform/tool companies that translate biological complexity into scalable technological products (not solely indications/drug plays).
Emphasis on partnering with "technical founders who view biology as technology's next frontier."
Runs Frontiers, a curated, deal-oriented summit (attendance capped at 250) to create high-quality investor-founder and strategic connections.
Extended network of seasoned advisors who engage with portfolio companies in fractional and advisory-board capacities.
Team composition includes scientific and technical operators (PhDs, data scientists), legal and M&A expertise, and investor/operators — signaling domain and transaction experience.